Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Invest Ophthalmol Vis Sci ; 63(1): 19, 2022 01 03.
Artículo en Inglés | MEDLINE | ID: mdl-35029636

RESUMEN

Purpose: The purpose of this study was to further expand the mutational spectrum of the Foveal Hypoplasia, Optic Nerve Decussation defect, and Anterior segment abnormalities (FHONDA syndrome), to describe the phenotypic spectrum, and to compare it to albinism. Subjects and Methods: We retrospectively collected molecular, ophthalmic, and electrophysiological data of 28 patients molecularly confirmed with FHONDA from the Netherlands (9), Israel (13), France (2), and the United States of America (4). We compared the data to that of 133 Dutch patients with the 3 most common types of albinism in the Netherlands: oculocutaneous albinism type 1 (49), type 2 (41), and ocular albinism (43). Results: Patients with FHONDA had a total of 15 different mutations in SLC38A8, of which 6 were novel. Excluding missing data, all patients had moderate to severe visual impairment (median visual acuity [VA] = 0.7 logMAR, interquartile range [IQR] = 0.6-0.8), nystagmus (28/28), and grade 4 foveal hypoplasia (17/17). Misrouting was present in all nine tested patients. None of the patients had any signs of hypopigmentation of skin and hair. VA in albinism was better (median = 0.5 logMAR, IQR = 0.3-0.7, P 0.006) and the phenotypes were more variable: 14 of 132 without nystagmus, foveal hypoplasia grades 1 to 4, and misrouting absent in 16 of 74. Conclusions: Compared to albinism, the FHONDA syndrome appears to have a more narrow phenotypic spectrum, consisting of nonprogressive moderately to severely reduced VA, nystagmus, severe foveal hypoplasia, and misrouting. The co-occurrence of nystagmus, foveal hypoplasia, and misrouting in the absence of hypopigmentation implies that these abnormalities are not caused by lack of melanin, which has important implications for understanding the pathogenesis of these features.


Asunto(s)
Albinismo Oculocutáneo/genética , Sistemas de Transporte de Aminoácidos Neutros/genética , Segmento Anterior del Ojo/anomalías , ADN/genética , Mutación , Agudeza Visual , Adolescente , Adulto , Anciano , Albinismo Oculocutáneo/diagnóstico , Albinismo Oculocutáneo/metabolismo , Sistemas de Transporte de Aminoácidos Neutros/metabolismo , Niño , Preescolar , Análisis Mutacional de ADN , Femenino , Estudios de Seguimiento , Fóvea Central/anomalías , Humanos , Lactante , Masculino , Persona de Mediana Edad , Fenotipo , Estudios Retrospectivos , Síndrome , Adulto Joven
2.
Semin Ophthalmol ; 34(4): 334-339, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31146612

RESUMEN

Objective: Microperimetry (MP) is used to assess visual sensitivity mediated by the central retina. As such, MP performance is a candidate outcome measure for gene therapy trials. Herein, we review MP results in three inherited retinal disorders for which gene therapy trials have been initiated-choroideremia, Stargardt disease, and X-linked juvenile retinoschisis. Each of these disorders typically presents in childhood and each has distinct effects on the central retina. Outcomes and Results: Our review indicates that microperimetry is feasible in each of these conditions. The MP sensitivity maps vary among conditions consistent with known effects of each of the three conditions. There is, however, within each of the three disorders considerable variability in fixation stability and in the pattern of sensitivity loss. Conclusions: Microperimetry is a valuable tool for monitoring functional aspects of central retina in an individual patient, especially in combination with other modalities such as OCT, autofluorescence, and acuity and thus may contribute to evaluating the efficacy of gene treatments. Variability of the MP parameters raises some cautions in application of MP as an outcome measure in treatment trials that may have small sample sizes. Nonetheless, we suspect that MP will continue to have a rightful place in future gene therapy trials.


Asunto(s)
Coroideremia/fisiopatología , Degeneración Macular/congénito , Retinosquisis/fisiopatología , Pruebas del Campo Visual/métodos , Campos Visuales/fisiología , Coroideremia/diagnóstico , Ensayos Clínicos como Asunto , Fijación Ocular/fisiología , Humanos , Degeneración Macular/diagnóstico , Degeneración Macular/fisiopatología , Retinosquisis/diagnóstico , Enfermedad de Stargardt
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA